Handelsbanken Fonder AB bought a new stake in Nuvalent, Inc. (NASDAQ:NUVL – Free Report) during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor bought 5,400 shares of the company’s stock, valued at approximately $397,000.
Several other large investors have also recently bought and sold shares of NUVL. Bank of New York Mellon Corp raised its holdings in Nuvalent by 0.7% in the 3rd quarter. Bank of New York Mellon Corp now owns 83,306 shares of the company’s stock valued at $3,830,000 after acquiring an additional 578 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in shares of Nuvalent by 460.3% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,849 shares of the company’s stock worth $177,000 after purchasing an additional 3,162 shares during the period. Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of Nuvalent by 16.1% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 14,866 shares of the company’s stock worth $683,000 after purchasing an additional 2,058 shares during the period. TD Asset Management Inc increased its holdings in shares of Nuvalent by 271.3% during the third quarter. TD Asset Management Inc now owns 45,524 shares of the company’s stock worth $2,093,000 after purchasing an additional 33,262 shares during the period. Finally, China Universal Asset Management Co. Ltd. increased its holdings in shares of Nuvalent by 97.2% during the third quarter. China Universal Asset Management Co. Ltd. now owns 1,327 shares of the company’s stock worth $61,000 after purchasing an additional 654 shares during the period. 97.26% of the stock is owned by institutional investors.
Analyst Upgrades and Downgrades
Several brokerages have recently commented on NUVL. JPMorgan Chase & Co. raised their target price on shares of Nuvalent from $68.00 to $98.00 and gave the stock an “overweight” rating in a report on Wednesday, March 6th. Jefferies Financial Group began coverage on shares of Nuvalent in a report on Wednesday, April 17th. They set a “buy” rating and a $97.00 target price on the stock. SVB Leerink raised shares of Nuvalent from a “market perform” rating to an “outperform” rating and raised their target price for the stock from $69.00 to $110.00 in a report on Monday, April 1st. Leerink Partnrs upgraded shares of Nuvalent from a “market perform” rating to an “outperform” rating in a research report on Monday, April 1st. Finally, BMO Capital Markets boosted their price objective on shares of Nuvalent from $93.00 to $102.00 and gave the company an “outperform” rating in a research report on Wednesday, February 28th. One equities research analyst has rated the stock with a hold rating and nine have issued a buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $90.78.
Insider Activity at Nuvalent
In related news, Director Andrew A. F. Hack sold 880,000 shares of the firm’s stock in a transaction on Wednesday, March 27th. The stock was sold at an average price of $72.77, for a total transaction of $64,037,600.00. Following the sale, the director now owns 2,697,267 shares of the company’s stock, valued at approximately $196,280,119.59. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. In related news, Director Matthew Shair sold 2,000 shares of the firm’s stock in a transaction on Monday, April 29th. The stock was sold at an average price of $67.51, for a total transaction of $135,020.00. Following the sale, the director now owns 236,522 shares of the company’s stock, valued at approximately $15,967,600.22. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Andrew A. F. Hack sold 880,000 shares of the firm’s stock in a transaction on Wednesday, March 27th. The shares were sold at an average price of $72.77, for a total value of $64,037,600.00. Following the sale, the director now directly owns 2,697,267 shares in the company, valued at approximately $196,280,119.59. The disclosure for this sale can be found here. Insiders have sold a total of 1,114,500 shares of company stock valued at $80,773,270 in the last 90 days. 14.77% of the stock is owned by corporate insiders.
Nuvalent Price Performance
Shares of NASDAQ:NUVL opened at $70.65 on Thursday. Nuvalent, Inc. has a one year low of $35.71 and a one year high of $89.39. The company has a market cap of $4.53 billion, a price-to-earnings ratio of -32.71 and a beta of 1.29. The firm has a 50 day simple moving average of $75.90 and a 200 day simple moving average of $71.25.
Nuvalent (NASDAQ:NUVL – Get Free Report) last announced its quarterly earnings results on Tuesday, February 27th. The company reported ($0.62) EPS for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.02). As a group, analysts expect that Nuvalent, Inc. will post -2.89 EPS for the current year.
About Nuvalent
Nuvalent, Inc, a clinical stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are NVL-520, a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the phase 2 portion of the ARROS-1 Phase 1/2 clinical trial; NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under the phase 2 portion of the ALKOVE-1 Phase 1/2 clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR, which is expected to initiate phase 1 trial.
Featured Stories
- Five stocks we like better than Nuvalent
- When to Sell a Stock for Profit or Loss
- AMD is Down 35%. Now is the Time to Buy the Dip
- High Flyers: 3 Natural Gas Stocks for March 2022
- Amazon Stands Tall: New Highs Are in Sight
- How Investors Can Find the Best Cheap Dividend Stocks
- Chesapeake Energy Stock is The Energy Play, Earnings Confirm
Want to see what other hedge funds are holding NUVL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Nuvalent, Inc. (NASDAQ:NUVL – Free Report).
Receive News & Ratings for Nuvalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuvalent and related companies with MarketBeat.com's FREE daily email newsletter.